Siobhain Mulrennan

Emailsiobhain.mulrennanuwa.eduau

The University of Western Australia (M570), 35 Stirling Highway,
6009 Perth
Australia

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Siobhain Mulrennan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

255 Citations
9 h-Index
20 Article
6 Abstract/Meeting Abstract
3 Letter
2 Conference paper
More

Clostridioides difficile colonization and infection in a cohort of Australian adults with cystic fibrosis
Tai, A. S., Putsathit, P., Eng, L., Imwattana, K., Collins, D. A., Mulrennan, S. & Riley, T. V., Jul 2021, In: Journal of Hospital Infection. 113, p. 44-51 8 p.
Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus)
Effect of transfer from a pediatric to adult cystic fibrosis center on clinical status and hospital attendance
Collins, R., Singh, B., Payne, D. N., Bharat, C., Noffsinger, W., Dhaliwal, S. S., O'Dea, C. & Mulrennan, S., 1 Apr 2021, (E-pub ahead of print) In: Pediatric Pulmonology.
Research output: Contribution to journal › Article › peer-review
Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis
Boyle, M., Mulrennan, S., Morey, S., Vekaria, S., Popowicz, N. & Tai, A., Jan 2021, In: Respirology Case Reports. 9, 1, e00696.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Citations (Scopus)
Novel method to select meaningful outcomes for evaluation in clinical trials
McLeod, C., Norman, R., Wood, J., Mulrennan, S., Morey, S., Schultz, A., Messer, M., Spaapen, K., Stoneham, M., Wu, Y., Smyth, A., Blyth, C., Webb, S., Mascaro, S., Woodberry, O. & Snelling, T., 7 Oct 2021, In: BMJ Open Respiratory Research. 8, 1, e000877.
Research output: Contribution to journal › Article › peer-review

Open Access
Medical information and social media in the time of COVID-19
Mulrennan, S. & Colt, H., 1 Jun 2020, In: Respirology. 25, 6, p. 578-579 2 p.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access

5 Citations (Scopus)

4 Active
5 Finished

A phase 3, Randomised,double-blind, controlled study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects with Cystic: Vertex Study Number : VX20-121-103
Mulrennan, S.
Vertex Pharmaceuticals (Aust) Pty Ltd
19/08/21 → 19/09/25
Project: Research
A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation
Mulrennan, S.
Vertex Pharmaceuticals (Aust) Pty Ltd
5/07/21 → 31/07/23
Project: Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis –The ASPEN Study
Mulrennan, S.
PPD PTY LTD
20/01/21 → 1/01/24
Project: Research
BEAT CF: Bayesian Evidence-Adaptive Treatment for managing Cystic Fibrosis
Mulrennan, S.
Medical Research Future Fund MRFF
1/09/20 → 31/08/23
Project: Research
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients with Cystic Fibrosis
Mulrennan, S.
Novotech (Australia) Pty Limited
1/09/20 → 31/08/21
Project: Research

Siobhain Mulrennan

Fingerprint

Network

Dive into details

Clostridioides difficile colonization and infection in a cohort of Australian adults with cystic fibrosis

Effect of transfer from a pediatric to adult cystic fibrosis center on clinical status and hospital attendance

Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis

Novel method to select meaningful outcomes for evaluation in clinical trials

Medical information and social media in the time of COVID-19

A phase 3, Randomised,double-blind, controlled study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects with Cystic: Vertex Study Number : VX20-121-103

A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis –The ASPEN Study

BEAT CF: Bayesian Evidence-Adaptive Treatment for managing Cystic Fibrosis

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients with Cystic Fibrosis

Siobhain Mulrennan

Fingerprint

Network

Research output

Projects